that ELN is still way undervalued yes. I still say Ty will outpace the initial sales estimates which drove ELN over $29 and the Alz program has progressed past the point where it drove ELN over $60. As SOON as Ty is back ELN will be stronger than it was when it was in the high $60s. So....even though ELN has done well lately, IMO it has lots of PPS to make up before it gets near its true value.
3 biotech analysts at JPM agree with you if Ty makes it back to the market.
We still have concerns about how long it will take ELN to get to profitability, but 2008 is a possibility now in our view. Our previous JPM survey of both physicians and patients suggested that the product could hit ~ $650M within 2 years of launch with a 14% share, which would be an upside to our forecasts. The European opportunity seems to have been largely overlooked by the Street.
IMO with Ty $30+. Nano = the + Then any good news from Alz program will push it over $40 --- depending on the news we could see over $60 in a year. Alz program is a wild card. If it hits $200+ is reasonable. (18months min)